Literature DB >> 17520171

Pericarditis: a rare complication of methotrexate therapy.

Tayyab Mohyuddin1, Mazen Elyan1, Irving Kushner2.   

Abstract

Serositis is a rare complication of methotrexate (MTX) administration. We report a 60-year-old man with rheumatoid arthritis who developed pericarditis after taking his weekly MTX dose, which recurred within hours after 2 subsequent weekly MTX doses. Pericarditis has not recurred after discontinuance of MTX over 3 years ago. We conclude that he had MTX-induced pericarditis, based on the close temporal relationship between MTX ingestion and manifestations of pericarditis on three distinct occasions because of the previous reports of MTX-induced pericarditis and because pericarditis has not recurred after MTX withdrawal.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17520171     DOI： 10.1007/s10067-007-0630-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  7 in total

1.  [Extra-articular manifestations of rheumatoid arthritis at the time of basic methotrexate treatment: apropos of a case of nodulosis with pericarditis].

Authors:  O Raccaud
Journal:  Rev Med Suisse Romande       Date:  1994-04

2.  Methotrexate induced pericarditis and pericardial effusion in psoriatic patient.

Authors:  P Palungwachira; P Palungwachira; P Laohathai
Journal:  J Med Assoc Thai       Date:  1998-02

3.  Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism.

Authors:  G M Akoun; S Gauthier-Rahman; C M Mayaud; J L Touboul; M F Denis
Journal:  Chest       Date:  1987-01       Impact factor: 9.410

4.  Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis.

Authors:  B Combe; C Didry; M Gutierrez; J M Anaya; J Sany
Journal:  Eur J Med       Date:  1993-03

5.  Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder.

Authors:  D A White; J A Rankin; D E Stover; R A Gellene; S Gupta
Journal:  Am Rev Respir Dis       Date:  1989-01

6.  Methotrexate-induced pericarditis and pericardial effusion; first reported case.

Authors:  L N Forbat; B W Hancock; A H Gershlick
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

7.  Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis.

Authors:  S Sharma; S Jagdev; R E Coleman; B W Hancock; P C Lorigan
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640
  7 in total
  4 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

2.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

Review 3.  Rituximab therapy in pericarditis associated with rheumatoid arthritis.

Authors:  Ali Taylan
Journal:  Rheumatol Int       Date:  2022-01-05       Impact factor: 3.580

4.  Current awareness: pharmacoepidemiology and drug safety.

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-06       Impact factor: 2.890
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.